Brief: Immunotech Biopharm Says Clinical Approval For Denocabtagene Ciloleucel Injection
21/03/2023 15:09
March 21 (Reuters) - Immunotech Biopharm 6978.HK :
* CLINICAL APPROVAL FOR DENOCABTAGENE CILOLEUCEL INJECTION
* OBTAINED CLINICAL APPROVAL FOR DENOCABTAGENE CILOLEUCEL
INJECTION FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION
* EXPECTS TO CONDUCT CLINICAL TRIAL OF DENOCABTAGENE
CILOLEUCEL
INJECTION IN 2023
Further company coverage: 6978.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunotech Biopharm
See all newsBrief: Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan
Brief: Immunotech Biopharm Receives Notice Of Rejection For Conditional New Drug Application For EAL Dated 27 April 2026
Brief: Trading In Shares Of Immunotech Biopharm Will Be Halted At 1:00 PM On April 28, HKEX Says
Brief: Immunotech Biopharm Posts Loss And Total Comprehensive Expense For Year Attributable Rmb230.8 Million
Brief: Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN